Ceff
|
The assumed effective number of contacts per infectious TB case.
|
N(1,1) truncated to be greater than 0.
|
|
Estimated using a dynamic model of TB transmission in England which found an effective contact rate of 1 in 1990. A conservative interval has then been applied.
|
Vynnycky et al.
|
Chisteff
|
The assumed historic effective number of contacts per infectious TB case.
|
U(Ceff,20)
|
|
Estimated using a dynamic model of TB transmission in England which found an effective contact rate of 1 in 1990 and 20 in 1901. A conservative interval has been chosen to represent the parameter uncertainty. It has been assumed that the historic contact rate is bounded below by the current contact rate.
|
Vynnycky et al.
|
Chalf-lifeeff
|
It is assumed that the historic effective contact rate decays from 1935 to 1980 with a half-life of C^{}_{}.
|
N(5,5) truncated to be greater than 0.
|
|
The prior distribution is informed by historic TB notifications.
|
Assumption
|
βyoung-adult
|
This parameter modifies the effective contact rate in scenarios when the transmission probability is modified for young adults (15-24).
|
U(0,10)
|
|
An uninformative prior has been used bounded above to restrict the transmission probability in young adults to be no greater than 10 times that in other age-groups.
|
Assumption
|
Υ
|
The age-specific proportion of cases that have pulmonary TB
|
Υ0−14,15−59,60−89=N(0.629,0.00101), N(0.706,0.00411), N(0.750,0.00569)
|
Proportion
|
Estimated using the age-specific proportion of cases that had pulmonary TB in the ETS.
|
Derived from data
|
ρ
|
The age-specific proportion of pulmonary TB cases that are smear positive
|
ρ0−14,15−59,60−89=N(0.302,0.0189), N(0.652,0.00518), N(0.536,0.00845)
|
Proportion
|
Estimated using the age-specific proportion of pulmonary TB cases that were smear postive in the ETS.
|
Derived from data
|
C
|
Matrix of contact rates between each age group
|
|
Non-unique yearly contacts.
|
For each parameter sample a contact matrix was bootstrapped from the POLYMOD survey data, standardised using the UK born population in 2005, and then averaged to provided a symmetric contact matrix.
|
Mossong et al.
|
ι(t)
|
The age-specific number of non-UK born pulmonary TB cases in England each year
|
|
Cases
|
The number of pulmonary non-UK born cases for each year were extracted from the ETS and grouped by age.
|
Derived from data
|
ιscale
|
Scaling parameter for the importation of non-UK born cases between 1960 and 2000.
|
N(0,200)
|
|
This largely uninformative prior range was chosen so that non-UK born scaling can vary between approximately linear to approximately constant.
|
Assumption
|
M
|
The proportion of mixing between the UK born and non-UK born population.
|
N(1,1) truncated to be greater than 0
|
Proportion
|
Any degree of mixing is allowed as there is little data on which to base this estimate. Mixing greater than 1 is allowed as this is used to represent non-UK born cases being in some way more infectious than non-UK born cases.
|
Assumption
|
Myoung-adult
|
This parameter modifies the non-UK born mixing rate in scenarios when M is modified for young adults (15-24).
|
U(0,10)
|
|
An uninformative prior has been used bounded above to restrict non-UK born mixing in young adults to be no greater than 10 times that in other age-groups.
|
Assumption
|
χ
|
Age-specific protection from infection with TB due to BCG vaccination
|
χvi=N(0.185, 0.0536), where i is the age group vaccinated.
|
Proportion
|
A meta-analysis of the protection from infection due to BCG vaccinatiion in children. It has been assumed that there is no reduction in protection in UK born adults.
|
Roy et al.
|
ϵH
|
The age-specific rate of transition to active disease during high risk latent period.
|
ϵ0−4,5−14,15−89H=N(0.00695,0.00130), N(0.0028,0.000561), N(0.000335,0.0000893)
|
days−1
|
From fitting a similar model to contact data in Australia, and Holland. Distribution derived by the assumption of a normal distribution based on 95% credible intervals.
|
Ragonnet et al.
|
κ
|
The reciprocal of the age-specific average high risk latent period.
|
κ0−4,5−14,15−89=N(0.0133,0.00242), N(0.0120,0.00207), N(0.00725,0.00191)
|
days−1
|
From fitting a similar model to contact data in Australia, and Holland. Distribution derived by the assumption of a normal distribution based on 95% credible intervals.
|
Ragonnet et al.
|
ϵL
|
The reciprocal of the age-specific average low risk latent period.
|
ϵ0−4,5−14,15−89L=N(8.00e−6,4.08e−6), N(9.84e−6,4.67e−6), N(5.95e−6,2.07e−6)
|
days−1
|
From fitting a similar model to contact data in Australia, and Holland. Distribution derived by the assumption of a normal distribution based on 95% credible intervals.
|
Ragonnet et al.
|
ϵolder-adultL
|
This parameter modifies the activation rate of low risk latent cases who are 70+ and reduces the activaton rate for other adults so that the mean activation rate is ϵ15−89L
|
N(2,0.5) truncated to be at least 1.
|
|
Evidence suggests that activation risk increases when individuals enter old age. A largely uninformative prior has been used centred around an increase in risk of double the average rate.
|
Horsburgh, Jr. et al.
|
αTi
|
The BCG vaccine effectiveness at preventing the development of active TB disease in a TB free population
|
αTi,i+5,i+10,i+15,i+20,i+25=1−eαln(T)i,i+5,i+10,i+15,i+20,i+25, where αln(T)i,i+5,i+10,i+15,i+20,i+25=N(−1.86,0.22), N(−1.19,0.24), N(−0.84,0.22), N(−0.84,0.2), N(−0.28,0.19), N(−0.23,0.29)) and i is the age group vaccinated
|
Proportion
|
Poisson regression used to calculate Risk Ratios from literature values. A distribution is then found using the log normal approximation. Effectiveness estimates are caculated using 1 minus the exponentiated log normal distribution.
|
Hart et al. and Mangtani et al.
|
δ
|
Reduction in susceptibilty to infection for low risk latent cases.
|
N(0.78, 0.0408)
|
Proportion
|
A review of prospective cohort studies of persons exposed to individuals with infectious tuberculosis that was published prior to the widespread treatment of latent tuberculosis.
|
Andrews et al.
|
νP,E
|
The reciprocal of the average infectious period
|
νP(0−14,15−89)=N(0.181,0.310)−1, N(0.328,0.447)−1, νE(0−14,15−89)=N(0.306,0.602)−1, N(0.480,0.866)−1
|
years−1
|
Estimated based on the time from initial symptoms to starting treatment
|
Derived from data
|
ϕ
|
The reciprocal of the time to succesful treatment completion
|
ϕ0−14,15−69,70−89=N(0.606,0.237)−1, N(0.645,0.290)−1, N(0.616,0.265)−1 and truncated to be greater than 4 months
|
years−1
|
Estimated based on the time from starting treatment to treatment completion.
|
Derived from data
|
μ
|
Rate of age-specific pulmonary/extra-pulmonary TB TB mortality
|
μ0−14,15−59,60−89=N(0.0039,0.018), N(0.0226,0.00787), N(0.117,0.0165) truncated to be greater than 0.
|
years−1
|
Estimated based on outcomes at 12 months where cause of death was known, including all-cause deaths in the denominator.
|
Derived from data
|
ζ
|
Rate of loss to follow up
|
ζ0−14,15−59,60−89=N(0.00976,0.0179), N(0.0304,0.00764), N(0.00614,0.0159), truncated to be greater than 0.
|
years−1
|
Estimated based on outcomes at 12 months for TB cases
|
Derived from data
|